Home Isis Pharmaceuticals Earns $2 Million from GSK for the Advancement of ISIS-TTR Rx
 

Keywords :   


Isis Pharmaceuticals Earns $2 Million from GSK for the Advancement of ISIS-TTR Rx

2013-12-03 00:36:37| Biotech - Topix.net

ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.

Tags: of million rx pharmaceuticals

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11Kim Madigan to chair 2025 FTA Fall Technical Conference
05.11PM responds to Sir Alan Bates after repeated requests
05.11American Angus elects 2024-25 board leaders
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Public Advisory Number 8A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
More »